Immune complexome analysis of serum samples from non-small-cell lung cancer patients identifies predictive biomarkers for nivolumab therapy
•We compared immune complex antigens between responders and non-responders for nivolumab therapy.•Combination of immune complex antigens may predict the therapeutic effect of nivolumab.•Immune complexome analysis identifies predictive biomarkers in ICI therapy. Immune checkpoint inhibitors (ICIs) ha...
Gespeichert in:
Veröffentlicht in: | Clinica chimica acta 2022-07, Vol.532, p.84-88 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 88 |
---|---|
container_issue | |
container_start_page | 84 |
container_title | Clinica chimica acta |
container_volume | 532 |
creator | Aizawa, Rika Nakamura, Yoichi Ikeda, Takaya Aibara, Nozomi Kutsuna, Yuki J. Kurosaki, Tomoaki Aki, Keisei Junya, Hashizume Nakagawa, Hiroo Sato, Kayoko Kodama, Yukinobu Nakashima, Mihoko N. Nakashima, Mikiro Mukae, Hiroshi Ohyama, Kaname |
description | •We compared immune complex antigens between responders and non-responders for nivolumab therapy.•Combination of immune complex antigens may predict the therapeutic effect of nivolumab.•Immune complexome analysis identifies predictive biomarkers in ICI therapy.
Immune checkpoint inhibitors (ICIs) have achieved important outcomes in cancer treatment. However, current clinical biomarker tests are not suitable for some patients because they require tumor tissues and have poor predictive value for treatment responses. Therefore, the identification of biomarkers that enable screening tests in all patients is necessary.
We performed an immune complexome analysis of non-small cell lung cancer patients treated with nivolumab to comprehensively identify and compare antigens incorporated into immune complexes (IC-antigens) in serum samples from the responders (n = 15) and non-responders (n = 20). Additionally, combinations of IC-antigens characteristic to the responder group were evaluated by logistic regression analysis and receiver operating characteristics curves to examine their predictiveness for ICI treatment responses.
The combination of predictive biomarkers detected before treatment was profilin-1, purine nucleoside phosphorylase, alpha-enolase, and nucleoside diphosphate kinase A [p = 0.0043, odds ratio = 2.26, 95% confidence interval (CI) = 1.19–4.28, area under the curve = 0.76]. The combination of predictive biomarkers detected after treatment was peptidyl-prolyl cis–trans isomerase A, ubiquitin-like modifier-activating enzyme 1, complement component C8 beta chain, and apolipoprotein L1 (p = 0.0039, odds ratio = 2.56, 95% CI = 1.25–5.23, area under the curve = 0.77).
Combinations of serum IC-antigens may predict the therapeutic effect of nivolumab in non-small cell lung cancer patients. |
doi_str_mv | 10.1016/j.cca.2022.05.021 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2674002978</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0009898122011731</els_id><sourcerecordid>2674002978</sourcerecordid><originalsourceid>FETCH-LOGICAL-c506t-ff23e92d71ba37f04af9788abfab8525dc855262fff46eef71d47e58aa117c2f3</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhS0EokPhAdggL9kk2M6PE7FCFS2VKnVT1taNcw0e_BPsZMQ8Ay-NR1O67OrK8jmfdM4h5D1nNWe8_7SvtYZaMCFq1tVM8BdkxwfZVE07ipdkxxgbq2Ec-AV5k_O-PFvW89fkoun6Xray35G_t95vAamOfnH4J3qkEMAds800GpoxbZ5mOH1malL0NMRQZQ_OVRqdo24LP6iGoDHRBVaLYc3UzuVYY4tnSThbvdoD0slGD-kXpkKKiQZ7iG7zMNH1JyZYjm_JKwMu47vHe0m-X399uPpW3d3f3F59uat0x_q1MkY0OIpZ8gkaaVgLZpTDAJOBaehEN-uh60QvjDFtj2gkn1uJ3QDAudTCNJfk45m7pPh7w7wqb_MpDASMW1aidMOYKNAi5WepTjHnhEYtyZYQR8WZOm2g9qpsoE4bKNapskHxfHjEb5PH-cnxv_Qi-HwWYAl5sJhU1qU3XYpKqFc1R_sM_h9IBptq</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2674002978</pqid></control><display><type>article</type><title>Immune complexome analysis of serum samples from non-small-cell lung cancer patients identifies predictive biomarkers for nivolumab therapy</title><source>Access via ScienceDirect (Elsevier)</source><creator>Aizawa, Rika ; Nakamura, Yoichi ; Ikeda, Takaya ; Aibara, Nozomi ; Kutsuna, Yuki J. ; Kurosaki, Tomoaki ; Aki, Keisei ; Junya, Hashizume ; Nakagawa, Hiroo ; Sato, Kayoko ; Kodama, Yukinobu ; Nakashima, Mihoko N. ; Nakashima, Mikiro ; Mukae, Hiroshi ; Ohyama, Kaname</creator><creatorcontrib>Aizawa, Rika ; Nakamura, Yoichi ; Ikeda, Takaya ; Aibara, Nozomi ; Kutsuna, Yuki J. ; Kurosaki, Tomoaki ; Aki, Keisei ; Junya, Hashizume ; Nakagawa, Hiroo ; Sato, Kayoko ; Kodama, Yukinobu ; Nakashima, Mihoko N. ; Nakashima, Mikiro ; Mukae, Hiroshi ; Ohyama, Kaname</creatorcontrib><description>•We compared immune complex antigens between responders and non-responders for nivolumab therapy.•Combination of immune complex antigens may predict the therapeutic effect of nivolumab.•Immune complexome analysis identifies predictive biomarkers in ICI therapy.
Immune checkpoint inhibitors (ICIs) have achieved important outcomes in cancer treatment. However, current clinical biomarker tests are not suitable for some patients because they require tumor tissues and have poor predictive value for treatment responses. Therefore, the identification of biomarkers that enable screening tests in all patients is necessary.
We performed an immune complexome analysis of non-small cell lung cancer patients treated with nivolumab to comprehensively identify and compare antigens incorporated into immune complexes (IC-antigens) in serum samples from the responders (n = 15) and non-responders (n = 20). Additionally, combinations of IC-antigens characteristic to the responder group were evaluated by logistic regression analysis and receiver operating characteristics curves to examine their predictiveness for ICI treatment responses.
The combination of predictive biomarkers detected before treatment was profilin-1, purine nucleoside phosphorylase, alpha-enolase, and nucleoside diphosphate kinase A [p = 0.0043, odds ratio = 2.26, 95% confidence interval (CI) = 1.19–4.28, area under the curve = 0.76]. The combination of predictive biomarkers detected after treatment was peptidyl-prolyl cis–trans isomerase A, ubiquitin-like modifier-activating enzyme 1, complement component C8 beta chain, and apolipoprotein L1 (p = 0.0039, odds ratio = 2.56, 95% CI = 1.25–5.23, area under the curve = 0.77).
Combinations of serum IC-antigens may predict the therapeutic effect of nivolumab in non-small cell lung cancer patients.</description><identifier>ISSN: 0009-8981</identifier><identifier>EISSN: 1873-3492</identifier><identifier>DOI: 10.1016/j.cca.2022.05.021</identifier><identifier>PMID: 35667476</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Immune complex antigen ; Immune complexome analysis ; Nivolumab ; Non-small-cell lung cancer ; Therapeutic predictive biomarker</subject><ispartof>Clinica chimica acta, 2022-07, Vol.532, p.84-88</ispartof><rights>2022 Elsevier B.V.</rights><rights>Copyright © 2022 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c506t-ff23e92d71ba37f04af9788abfab8525dc855262fff46eef71d47e58aa117c2f3</citedby><cites>FETCH-LOGICAL-c506t-ff23e92d71ba37f04af9788abfab8525dc855262fff46eef71d47e58aa117c2f3</cites><orcidid>0000-0002-1449-5505</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.cca.2022.05.021$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35667476$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aizawa, Rika</creatorcontrib><creatorcontrib>Nakamura, Yoichi</creatorcontrib><creatorcontrib>Ikeda, Takaya</creatorcontrib><creatorcontrib>Aibara, Nozomi</creatorcontrib><creatorcontrib>Kutsuna, Yuki J.</creatorcontrib><creatorcontrib>Kurosaki, Tomoaki</creatorcontrib><creatorcontrib>Aki, Keisei</creatorcontrib><creatorcontrib>Junya, Hashizume</creatorcontrib><creatorcontrib>Nakagawa, Hiroo</creatorcontrib><creatorcontrib>Sato, Kayoko</creatorcontrib><creatorcontrib>Kodama, Yukinobu</creatorcontrib><creatorcontrib>Nakashima, Mihoko N.</creatorcontrib><creatorcontrib>Nakashima, Mikiro</creatorcontrib><creatorcontrib>Mukae, Hiroshi</creatorcontrib><creatorcontrib>Ohyama, Kaname</creatorcontrib><title>Immune complexome analysis of serum samples from non-small-cell lung cancer patients identifies predictive biomarkers for nivolumab therapy</title><title>Clinica chimica acta</title><addtitle>Clin Chim Acta</addtitle><description>•We compared immune complex antigens between responders and non-responders for nivolumab therapy.•Combination of immune complex antigens may predict the therapeutic effect of nivolumab.•Immune complexome analysis identifies predictive biomarkers in ICI therapy.
Immune checkpoint inhibitors (ICIs) have achieved important outcomes in cancer treatment. However, current clinical biomarker tests are not suitable for some patients because they require tumor tissues and have poor predictive value for treatment responses. Therefore, the identification of biomarkers that enable screening tests in all patients is necessary.
We performed an immune complexome analysis of non-small cell lung cancer patients treated with nivolumab to comprehensively identify and compare antigens incorporated into immune complexes (IC-antigens) in serum samples from the responders (n = 15) and non-responders (n = 20). Additionally, combinations of IC-antigens characteristic to the responder group were evaluated by logistic regression analysis and receiver operating characteristics curves to examine their predictiveness for ICI treatment responses.
The combination of predictive biomarkers detected before treatment was profilin-1, purine nucleoside phosphorylase, alpha-enolase, and nucleoside diphosphate kinase A [p = 0.0043, odds ratio = 2.26, 95% confidence interval (CI) = 1.19–4.28, area under the curve = 0.76]. The combination of predictive biomarkers detected after treatment was peptidyl-prolyl cis–trans isomerase A, ubiquitin-like modifier-activating enzyme 1, complement component C8 beta chain, and apolipoprotein L1 (p = 0.0039, odds ratio = 2.56, 95% CI = 1.25–5.23, area under the curve = 0.77).
Combinations of serum IC-antigens may predict the therapeutic effect of nivolumab in non-small cell lung cancer patients.</description><subject>Immune complex antigen</subject><subject>Immune complexome analysis</subject><subject>Nivolumab</subject><subject>Non-small-cell lung cancer</subject><subject>Therapeutic predictive biomarker</subject><issn>0009-8981</issn><issn>1873-3492</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kc1u1DAUhS0EokPhAdggL9kk2M6PE7FCFS2VKnVT1taNcw0e_BPsZMQ8Ay-NR1O67OrK8jmfdM4h5D1nNWe8_7SvtYZaMCFq1tVM8BdkxwfZVE07ipdkxxgbq2Ec-AV5k_O-PFvW89fkoun6Xray35G_t95vAamOfnH4J3qkEMAds800GpoxbZ5mOH1malL0NMRQZQ_OVRqdo24LP6iGoDHRBVaLYc3UzuVYY4tnSThbvdoD0slGD-kXpkKKiQZ7iG7zMNH1JyZYjm_JKwMu47vHe0m-X399uPpW3d3f3F59uat0x_q1MkY0OIpZ8gkaaVgLZpTDAJOBaehEN-uh60QvjDFtj2gkn1uJ3QDAudTCNJfk45m7pPh7w7wqb_MpDASMW1aidMOYKNAi5WepTjHnhEYtyZYQR8WZOm2g9qpsoE4bKNapskHxfHjEb5PH-cnxv_Qi-HwWYAl5sJhU1qU3XYpKqFc1R_sM_h9IBptq</recordid><startdate>20220701</startdate><enddate>20220701</enddate><creator>Aizawa, Rika</creator><creator>Nakamura, Yoichi</creator><creator>Ikeda, Takaya</creator><creator>Aibara, Nozomi</creator><creator>Kutsuna, Yuki J.</creator><creator>Kurosaki, Tomoaki</creator><creator>Aki, Keisei</creator><creator>Junya, Hashizume</creator><creator>Nakagawa, Hiroo</creator><creator>Sato, Kayoko</creator><creator>Kodama, Yukinobu</creator><creator>Nakashima, Mihoko N.</creator><creator>Nakashima, Mikiro</creator><creator>Mukae, Hiroshi</creator><creator>Ohyama, Kaname</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1449-5505</orcidid></search><sort><creationdate>20220701</creationdate><title>Immune complexome analysis of serum samples from non-small-cell lung cancer patients identifies predictive biomarkers for nivolumab therapy</title><author>Aizawa, Rika ; Nakamura, Yoichi ; Ikeda, Takaya ; Aibara, Nozomi ; Kutsuna, Yuki J. ; Kurosaki, Tomoaki ; Aki, Keisei ; Junya, Hashizume ; Nakagawa, Hiroo ; Sato, Kayoko ; Kodama, Yukinobu ; Nakashima, Mihoko N. ; Nakashima, Mikiro ; Mukae, Hiroshi ; Ohyama, Kaname</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c506t-ff23e92d71ba37f04af9788abfab8525dc855262fff46eef71d47e58aa117c2f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Immune complex antigen</topic><topic>Immune complexome analysis</topic><topic>Nivolumab</topic><topic>Non-small-cell lung cancer</topic><topic>Therapeutic predictive biomarker</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aizawa, Rika</creatorcontrib><creatorcontrib>Nakamura, Yoichi</creatorcontrib><creatorcontrib>Ikeda, Takaya</creatorcontrib><creatorcontrib>Aibara, Nozomi</creatorcontrib><creatorcontrib>Kutsuna, Yuki J.</creatorcontrib><creatorcontrib>Kurosaki, Tomoaki</creatorcontrib><creatorcontrib>Aki, Keisei</creatorcontrib><creatorcontrib>Junya, Hashizume</creatorcontrib><creatorcontrib>Nakagawa, Hiroo</creatorcontrib><creatorcontrib>Sato, Kayoko</creatorcontrib><creatorcontrib>Kodama, Yukinobu</creatorcontrib><creatorcontrib>Nakashima, Mihoko N.</creatorcontrib><creatorcontrib>Nakashima, Mikiro</creatorcontrib><creatorcontrib>Mukae, Hiroshi</creatorcontrib><creatorcontrib>Ohyama, Kaname</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinica chimica acta</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aizawa, Rika</au><au>Nakamura, Yoichi</au><au>Ikeda, Takaya</au><au>Aibara, Nozomi</au><au>Kutsuna, Yuki J.</au><au>Kurosaki, Tomoaki</au><au>Aki, Keisei</au><au>Junya, Hashizume</au><au>Nakagawa, Hiroo</au><au>Sato, Kayoko</au><au>Kodama, Yukinobu</au><au>Nakashima, Mihoko N.</au><au>Nakashima, Mikiro</au><au>Mukae, Hiroshi</au><au>Ohyama, Kaname</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immune complexome analysis of serum samples from non-small-cell lung cancer patients identifies predictive biomarkers for nivolumab therapy</atitle><jtitle>Clinica chimica acta</jtitle><addtitle>Clin Chim Acta</addtitle><date>2022-07-01</date><risdate>2022</risdate><volume>532</volume><spage>84</spage><epage>88</epage><pages>84-88</pages><issn>0009-8981</issn><eissn>1873-3492</eissn><abstract>•We compared immune complex antigens between responders and non-responders for nivolumab therapy.•Combination of immune complex antigens may predict the therapeutic effect of nivolumab.•Immune complexome analysis identifies predictive biomarkers in ICI therapy.
Immune checkpoint inhibitors (ICIs) have achieved important outcomes in cancer treatment. However, current clinical biomarker tests are not suitable for some patients because they require tumor tissues and have poor predictive value for treatment responses. Therefore, the identification of biomarkers that enable screening tests in all patients is necessary.
We performed an immune complexome analysis of non-small cell lung cancer patients treated with nivolumab to comprehensively identify and compare antigens incorporated into immune complexes (IC-antigens) in serum samples from the responders (n = 15) and non-responders (n = 20). Additionally, combinations of IC-antigens characteristic to the responder group were evaluated by logistic regression analysis and receiver operating characteristics curves to examine their predictiveness for ICI treatment responses.
The combination of predictive biomarkers detected before treatment was profilin-1, purine nucleoside phosphorylase, alpha-enolase, and nucleoside diphosphate kinase A [p = 0.0043, odds ratio = 2.26, 95% confidence interval (CI) = 1.19–4.28, area under the curve = 0.76]. The combination of predictive biomarkers detected after treatment was peptidyl-prolyl cis–trans isomerase A, ubiquitin-like modifier-activating enzyme 1, complement component C8 beta chain, and apolipoprotein L1 (p = 0.0039, odds ratio = 2.56, 95% CI = 1.25–5.23, area under the curve = 0.77).
Combinations of serum IC-antigens may predict the therapeutic effect of nivolumab in non-small cell lung cancer patients.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>35667476</pmid><doi>10.1016/j.cca.2022.05.021</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-1449-5505</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0009-8981 |
ispartof | Clinica chimica acta, 2022-07, Vol.532, p.84-88 |
issn | 0009-8981 1873-3492 |
language | eng |
recordid | cdi_proquest_miscellaneous_2674002978 |
source | Access via ScienceDirect (Elsevier) |
subjects | Immune complex antigen Immune complexome analysis Nivolumab Non-small-cell lung cancer Therapeutic predictive biomarker |
title | Immune complexome analysis of serum samples from non-small-cell lung cancer patients identifies predictive biomarkers for nivolumab therapy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T15%3A24%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immune%20complexome%20analysis%20of%20serum%20samples%20from%20non-small-cell%20lung%20cancer%20patients%20identifies%20predictive%20biomarkers%20for%20nivolumab%20therapy&rft.jtitle=Clinica%20chimica%20acta&rft.au=Aizawa,%20Rika&rft.date=2022-07-01&rft.volume=532&rft.spage=84&rft.epage=88&rft.pages=84-88&rft.issn=0009-8981&rft.eissn=1873-3492&rft_id=info:doi/10.1016/j.cca.2022.05.021&rft_dat=%3Cproquest_cross%3E2674002978%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2674002978&rft_id=info:pmid/35667476&rft_els_id=S0009898122011731&rfr_iscdi=true |